Humana (NYSE:HUM) Issues Earnings Results, Beats Estimates By $0.10 EPS

Humana (NYSE:HUM) released its earnings results on Tuesday. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10, Zacks reports. Humana had a net margin of 1.18% and a return on equity of 13.20%. Humana updated its FY 2025 guidance to 16.250-16.250 EPS.

Humana Stock Performance

Shares of NYSE:HUM opened at $259.93 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The business’s fifty day moving average price is $273.00 and its two-hundred day moving average price is $295.72. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The stock has a market capitalization of $31.30 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56.

Analyst Ratings Changes

HUM has been the topic of a number of recent research reports. Barclays boosted their target price on Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 22nd. TD Cowen boosted their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 price target on shares of Humana in a research note on Wednesday. Finally, Wells Fargo & Company decreased their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus target price of $292.26.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.32% of the stock is owned by insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.